Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer

BACKGROUND: The efficacy difference between the second‐ and third‐generation of anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs) after crizotinib failure in advanced ALK‐positive non–small cell lung cancer (NSCLC) has not been clarified. This study evaluates the efficacy of different...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiya, Yang, Shaoxing, Zhang, Kun, Xu, Jing, Lv, Panpan, Gao, Hongjun, Qin, Haifeng, Wang, Hong, Liu, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200878/
https://www.ncbi.nlm.nih.gov/pubmed/35560808
http://dx.doi.org/10.1111/1759-7714.14455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200878/
https://www.ncbi.nlm.nih.gov/pubmed/35560808
http://dx.doi.org/10.1111/1759-7714.14455

Ejemplares similares